Cargando…

New drug approvals in acute myeloid leukemia: what’s the best end point?

Detalles Bibliográficos
Autores principales:	Estey, E, Othus, M, Lee, S J, Appelbaum, F R, Gale, R P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4777773/ https://www.ncbi.nlm.nih.gov/pubmed/26677969 http://dx.doi.org/10.1038/leu.2015.262

Ejemplares similares

Prediction of CR following a second course of ‘7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course
por: Othus, M, et al.
Publicado: (2016)

Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms
por: Shih, Lauren, et al.
Publicado: (2023)

Relative survival following response to 7+3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes:An analysis of four SWOG studies
por: Othus, Megan, et al.
Publicado: (2018)

Improved outcomes with “7+3” induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data
por: Othus, Megan, et al.
Publicado: (2022)

Effect of Measurable (“Minimal”) Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia
por: Othus, Megan, et al.
Publicado: (2016)

Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms
por: Paras, Gabrielle, et al.
Publicado: (2022)

Recent drug approvals for acute myeloid leukemia
por: Lai, Catherine, et al.
Publicado: (2019)

Pre- and Post-Transplant Quantification of Measurable (“Minimal”) Residual Disease via Multiparameter Flow Cytometry in Adult Acute Myeloid Leukemia
por: Zhou, Yi, et al.
Publicado: (2016)

Advances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development
por: Stanchina, Michele, et al.
Publicado: (2020)

Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
por: Godwin, Colin D., et al.
Publicado: (2022)

Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia
por: Orvain, Corentin, et al.
Publicado: (2023)

Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification
por: Hochman, Michael J., et al.
Publicado: (2023)

Effect of Genetic Profiling on Prediction of Therapeutic Resistance and Survival in Adult Acute Myeloid Leukemia
por: Walter, Roland B., et al.
Publicado: (2015)

Optimizing Use of Newly Approved Agents for Acute Myeloid Leukemia
por: Nix, Nancy M., et al.
Publicado: (2019)

Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia
por: Michelson, Andrew P., et al.
Publicado: (2020)

Paradigm Shift in the Management of Acute Myeloid Leukemia—Approved Options in 2023
por: Premnath, Naveen, et al.
Publicado: (2023)

Utility of Treatment-Related Mortality (TRM) Score to Predict Outcomes of Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation
por: Zarling, Lucas C., et al.
Publicado: (2022)

Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia
por: Orvain, Corentin, et al.
Publicado: (2022)

Regimen‐intensity per count‐recovery and hospitalization index: A new tool to assign regimen intensity for AML
por: Sorror, Mohamed L., et al.
Publicado: (2020)

FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
por: Chen, Emerson Y., et al.
Publicado: (2020)

Efficacy End Points and Dose Analysis of Food and Drug Administration-Approved Novel Drugs in 2020
por: Tang, Albert
Publicado: (2022)

Check(point) or checkmate for acute myeloid leukemia?
por: Niyongere, Sandrine, et al.
Publicado: (2021)

Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation
por: Rodríguez-Arbolí, Eduardo, et al.
Publicado: (2022)

Will immune therapy cure acute myeloid leukemia?
por: Gale, Robert Peter
Publicado: (2019)

Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of Mortality
por: Sorror, Mohamed L., et al.
Publicado: (2017)

Clinical value of new drugs in acute myeloid leukemia
por: Ossenkoppele, Gert
Publicado: (2019)

Can Immune Therapy Cure Acute Myeloid Leukemia?
por: Gale, Robert Peter
Publicado: (2023)

Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms: A Phase 1/2 Study
por: Halpern, Anna B., et al.
Publicado: (2017)

The treatment-related mortality score is associated with non-fatal adverse events following intensive AML induction chemotherapy
por: Buckley, S A, et al.
Publicado: (2015)

Low-intensity induction in acute myeloid leukemia. Always in the patients' best interest?
por: Atallah, Ehab
Publicado: (2022)

Potential Approaches Versus Approved or Developing Chronic Myeloid Leukemia Therapy
por: Andretta, Emanuela, et al.
Publicado: (2021)

Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia
por: Aureli, Anna, et al.
Publicado: (2021)

Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML)
por: Acharya, Utkarsh H., et al.
Publicado: (2018)

Dose intensity for induction in acute myeloid leukemia: what, when, and for whom?
por: McCurdy, Shannon R., et al.
Publicado: (2021)

Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation
por: Morsink, Linde M., et al.
Publicado: (2020)

Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network
por: Termini, Christina M., et al.
Publicado: (2023)

Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia
por: Cortes, Jorge E., et al.
Publicado: (2020)

Assessment of Surrogate End Point Trends in Clinical Trials to Approve Oncology Drugs From 2001 to 2020 in Japan
por: Maeda, Hideki, et al.
Publicado: (2023)

Drug Repurposing for the Treatment of Acute Myeloid Leukemia
por: Andresen, Vibeke, et al.
Publicado: (2017)

Mechanisms of drug resistance in acute myeloid leukemia
por: Zhang, Jing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i8fld79emvpql0vtj4bquinmr7